These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 28063331)

  • 41. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
    Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
    Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
    Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
    Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
    Gerber B; Loibl S; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Untch M; von Minckwitz G;
    Ann Oncol; 2013 Dec; 24(12):2978-84. PubMed ID: 24136883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
    Futamura M; Oba M; Masuda N; Bando H; Okada M; Yamamoto Y; Kin T; Saeki T; Nagashima T; Kuwayama T; Toh U; Hirano A; Inokuchi M; Yamagami K; Mizuno Y; Kojima Y; Nakayama T; Yasojima H; Ohno S
    Breast Cancer; 2021 Sep; 28(5):1023-1037. PubMed ID: 33811599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients.
    Kanazawa T; Akashi-Tanaka S; Iwamoto E; Takasugi M; Shien T; Kinoshita T; Miyakawa K; Shimizu C; Ando M; Katsumata N; Fujiwara Y; Fukutomi T
    Breast J; 2005; 11(5):311-6. PubMed ID: 16174150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer.
    Shien T; Kinoshita T; Seki K; Yoshida M; Hojo T; Shimizu C; Taira N; Doihara H; Akashi-Tanaka S; Tsuda H; Fujiwara Y
    Acta Med Okayama; 2013; 67(3):165-70. PubMed ID: 23804139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).
    Takada M; Ishiguro H; Nagai S; Ohtani S; Kawabata H; Yanagita Y; Hozumi Y; Shimizu C; Takao S; Sato N; Kosaka Y; Sagara Y; Iwata H; Ohno S; Kuroi K; Masuda N; Yamashiro H; Sugimoto M; Kondo M; Naito Y; Sasano H; Inamoto T; Morita S; Toi M
    Breast Cancer Res Treat; 2014 May; 145(1):143-53. PubMed ID: 24682674
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
    Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
    J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study.
    Dodiya HG; Brahmbhatt AP; Khatri PK; Kaushal AM; Vijay DG
    J Cancer Res Ther; 2015; 11(3):612-6. PubMed ID: 26458590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome after neoadjuvant chemotherapy in Asian breast cancer patients.
    Lim LY; Miao H; Lim JS; Lee SC; Bhoo-Pathy N; Yip CH; Taib NA; Chan P; Tan EY; Lim SH; Lim GH; Woo E; Tan YS; Lee JA; Wong M; Tan PH; Ong KW; Wong FY; Yap YS; Hartman M
    Cancer Med; 2017 Jan; 6(1):173-185. PubMed ID: 28000426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
    von Minckwitz G; Untch M; Nüesch E; Loibl S; Kaufmann M; Kümmel S; Fasching PA; Eiermann W; Blohmer JU; Costa SD; Mehta K; Hilfrich J; Jackisch C; Gerber B; du Bois A; Huober J; Hanusch C; Konecny G; Fett W; Stickeler E; Harbeck N; Müller V; Jüni P
    Breast Cancer Res Treat; 2011 Jan; 125(1):145-56. PubMed ID: 21042932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
    Dörfel S; Steffens CC; Meyer D; Tesch H; Kruggel L; Frank M; Jänicke M; Marschner N;
    Breast Cancer; 2018 May; 25(3):275-283. PubMed ID: 29204847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy?
    Coelho RC; Da Silva FML; Do Carmo IML; Bonaccorsi BV; Hahn SM; Faroni LD
    Breast; 2017 Feb; 31():192-196. PubMed ID: 27889595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
    Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
    J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
    Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
    Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
    Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
    Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients.
    Schwentner L; Wolters R; Wischnewsky M; Kreienberg R; Wöckel A
    Breast; 2012 Apr; 21(2):171-7. PubMed ID: 21945313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.